Completed PHASE3 INTERVENTIONAL 4-arm NCT01389167

Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia

Sponsor: National Institute on Drug Abuse (NIDA)

Interventions BDRC Medical Management Naltrexone (oral) Vivitrol

Updated 7 times since 2017 Last updated: Jan 9, 2018 Started: Sep 30, 2011 Primary completion: Sep 30, 2016 Completion: May 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01389167, this PHASE3 trial focuses on Opiate Dependence and remains completed. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE3

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)
St. Petersburg State Pavlov Medical University
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Petersburg, Russia